9Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-989
10Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147
6Colevas AD,Setser A,CTEP/NCI,et al.The NCI common Terminology Criteria for Adverse Events (CTCAE) v3.0 is the new standard for oncology clinical trials[J].Clin Oncol,2008,22(14S):176-181.
7Glinelius B,Ekstrom K,Hoffman K,et al.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer[J].Ann Oncol,2010,8:163-168.
8Giuliani F,Gebbia V,De Vita F,et al.Docetaxel as salvage therapy in advanced gastric cancer:a phase Ⅱ study of the Gruppo Oncologico Italia Meridionale (G.O.I.M)[J].Anticancer Res,2003,23(5b):65-67.
9Tsukamoto T,Mizoshita T, Tatematsu M. Animal models of stomach eareinogenesis[J].Toxicol Pathol, 2007,35(5) : 636-648.
10Nergiz I, Baseskioglu B, Yenilmez A, et all. Effects of rote- none on inducible nitric oxide synthase and cyclooxygenase-2 mRNA levels detected by real-time PCR in a rat bladder iscbe- mia/reperfusion model[J].Exp Ther Med.2012,4(2) :344-348.
